摘要
Background: The transformation of epidermal growth factor receptor (EGFR )-mutant lung adenocarcinoma (LUAD) into small cell lung cancer (SCLC) accounts for 3-14% of the resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). At present, there is no relevant research to explore the dynamic expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed SCLC/neuroendocrine carcinoma (NEC). Methods: Genetic analysis and protein level analysis by next-generation sequencing (NGS), Wholeexome sequencing (WES) and immunohistochemistry were performed to explore expression of EGFRmutant proteins and genomic evolution in EGFR-mutant transformed SCLC. The research used three patient-derived organoids (PDOs) to explore the efficacy of combo [chemotherapy (chemo) plus TKI or bevacizumab] treatment. According to the subsequent treatment regimens after SCLC/NEC transformation, 35 patients were divided into chemo (n=21) and combo (n=14) groups. Results: EGFR L858R and EGFR E746-750 del protein expression by immunohistochemistry was 80.0% (4/5) and 100% (6/6), respectively (P=0.455) in initially-transformed tissues. Meanwhile, EGFR-mutant proteins were expressed in 85.7% (6/7) of dynamic rebiopsy tissues or effusion samples after the first transformation. Then, by the pathway enrichment analysis of tissue and plasma NGS, the EGFR-related pathways were still activated after SCLC/NEC transformation. Moreover, WES analysis revealed that transformed SCLC shared a common clonal origin from the baseline LUAD. The drug sensitivity of three PDOs demonstrated potent anti-cancer activity of EGFR-TKIs plus chemo, compared with chemo or TKI alone. There were significant differences in objective response rate (ORR) between the combo and chemo groups [42.9 % vs. 4.8%, P=0.010, 95% confidence interval (CI): 1.5-145.2]. Furthermore, the median posttransformation progression-free survival (pPFS) was significantly prolonged in the combo group, with 5.4 Conclusions: EGFR 19del or L858R-mutant proteins could be constantly expressed, and EGFR pathway still existed in EGFR-mutant transformed SCLC/NEC with a common clonal origin from the baseline LUAD. Taking together, these molecular characteristics potentially favored clinical efficacy in transformed SCLC/NEC treated with the combo regimen.
学科与关键词
- A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survivalZhang, Chan-Yuan; Sun, Hao; Su, Jun-Wei; Chen, Yu-Qing; Zhang, Shi-Ling; Zheng, Ming-Ying; Li, Yu-Fa; Huang, Jie; Zhang, Chao; Tai, Zai-Xian; Cai, Miao; Zhang, Xu-Chao; Su, Jian; Xu, Chong-Rui; Yan, Hong-Hong; Chen, Hua-Jun; Wu, Yi-Long*; Yang, Jin-Ji*Lung Cancer, 2023, 175: 68-78.被引 6
- Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapyLu, Yiyu; Li, Zhihua; Zhu, Huawei; Zhao, Juan; Xu, Mian; Gu, Weiguang*Annals of Palliative Medicine, 2021, 10(12): 12886-12893.被引 1
- Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung AdenocarcinomaZhang, C.; Zhang, S.; Yao, Y.; Gao, Y.; Huang, J.; Peng, K.; Gao, Q.; Chen, H.; Xu, C.; Zhang, X.; Wu, Y.; Yang, J.被引 3
